TpG News and Research

RSS
Thousands got Exactech knee or hip replacements. Then, patients say, the parts began to fail.

Thousands got Exactech knee or hip replacements. Then, patients say, the parts began to fail.

Sick profit: Investigating private equity’s stealthy takeover of health care across cities and specialties

Sick profit: Investigating private equity’s stealthy takeover of health care across cities and specialties

Dartmouth launches new initiative for innovations in cancer care

Dartmouth launches new initiative for innovations in cancer care

Par Pharmaceutical files registration statement with SEC for initial public offering of common stock

Par Pharmaceutical files registration statement with SEC for initial public offering of common stock

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Chindex revenues increase 21% to $55.5M in second quarter 2014

Chindex revenues increase 21% to $55.5M in second quarter 2014

Virobay announces closing of expanded Series B second tranche financing

Virobay announces closing of expanded Series B second tranche financing

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy secures $49M in oversubscribed Series D round of financing

Epirus Biopharmaceuticals to merge with Zalicus

Epirus Biopharmaceuticals to merge with Zalicus

Chindex revenue increases 12% to $48.8M in fourth quarter 2013

Chindex revenue increases 12% to $48.8M in fourth quarter 2013

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories enters into definitive agreement to acquire Aptalis

Forest Laboratories enters into definitive agreement to acquire Aptalis

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

TPG acquires Par Pharmaceutical Companies

TPG acquires Par Pharmaceutical Companies

CardioDx completes two-tranche equity financing

CardioDx completes two-tranche equity financing

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Roka raises $47.5M in Series D round

Roka raises $47.5M in Series D round

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

Roka Bioscience raises $20M in Series C equity financing

Roka Bioscience raises $20M in Series C equity financing